M&T Bank Corp Editas Medicine, Inc. Transaction History

M&T Bank Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	SELL	$39.71 - $90.58 $167,615 - $382,338	-4,221 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$27.07 - $84.35 $190,085 - $592,305	-7,022 Reduced 62.46%	4,221 $296,000
Q3 2020 Nov 06, 2020	BUY	$28.06 - $37.16 $533 - $706	19 Added 0.17%	11,243 $315,000
Q2 2020 Jul 29, 2020	SELL	$18.5 - $34.34 $20,331 - $37,739	-1,099 Reduced 8.92%	11,224 $332,000
Q1 2020 May 14, 2020	BUY	$14.88 - $32.78 $7,276 - $16,029	489 Added 4.13%	12,323 $244,000
Q4 2019 Feb 07, 2020	SELL	$19.49 - $32.63 $409 - $685	-21 Reduced 0.18%	11,834 $350,000
Q3 2019 Nov 12, 2019	BUY	$22.49 - $26.81 $6,544 - $7,801	291 Added 2.52%	11,855 $270,000
Q2 2019 Aug 12, 2019	SELL	$20.48 - $27.76 $36,065 - $48,885	-1,761 Reduced 13.22%	11,564 $286,000
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $258,904 - $351,913	13,325 New	13,325 $326,000
Q4 2018 Feb 01, 2019	SELL	$18.19 - $31.79 $128,348 - $224,310	-7,056 Closed	0 $0
Q1 2018 May 04, 2018	SELL	$29.84 - $44.08 $55,412 - $81,856	-1,857 Reduced 20.83%	7,056 $234,000
Q3 2017 Nov 13, 2017	BUY	$15.81 - $24.01 $140,914 - $214,001	8,913	8,913 $214,000

250

56.9M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $94.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of M&T Bank Corp, based on Form 13F filings with the SEC.

Stay updated on M&T Bank Corp with notifications on news.